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promised patient confidentiality, as it allowed identi- 
fication of these individuals. The significant differences 
in practice prompted a survey of 11 other hospitals 
within the Yorkshire region, which revealed that these 
disparities were not confined to our organisation. CBW 
was rejected on grounds of preparation time, staff safety 
and patient confidentiality. Non-carbonated bottled 
water was rejected because of poor microbiological 
quality. Carbonated water, although microbiologically 
safer, was not acceptable to patients with chemotherapy- 
associated mucositis. SBW, as with other bottled water 
types, was relatively expensive and had poor organo- 
leptic quality. There were also logistical problems in 
delivery to, and storage of bottles on, units citywide. FW 
met criteria 1 to 3 and compared favourably with bottled 
water in terms of cost. FW has now been accepted as the 
preferred method of providing water to IC patients in 
our organisation 
Conclusion: Striking disparities in provision of potable 
water for IC patients as identified locally and regionally 
are of concern and we recommend that national 
guidelines are developed to ensure that IC patients 
receive safe drinking water. We would advocate that 
consideration should be given to filtered water in the 
drawing up of such guidelines 
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Objectives: Bacteremia due to Escherichia coli (ECB) is 
still the most common causes of infection in patients 
with hematologic malignancies in our center. 
Methods: The clinical characteristics of ECB in 2001 
were evaluated retrospectively. The results were com- 
pared with a control group with vancomycin resistant 
enterococci bacteremia (VREB). 
Results: Total 85 patients experienced the ECB in 
the year of 2001. Age, sex ratio, SAPS11 score were 
not different statistically from each other group. The 
Underlying diseases in ECB were acute myloid leu- 
kemia (AML) (63.5%) acute lymphoblastic leukemia 
(ALL) (34.1%) and the type of therapy were induction 
or reinduction chemotherapy(37.7%), consolidation 
chemotherapy (35.3%) allogeneic bone marrow trans- 
plant (BMT) (13.0%) autologous BMT (10.6%). The 
underlying diseases and type of therapy were different 
from each other group (P<O.OOl, .04). Neutropenia was 
more prevalent in the ECB group (P=O.OOl), but 
neutropenia and hospitalization were more prolonged in 
the VREB group (P= .006, .006). Co-infection was more 
common in the VREB group (P<O.OOl). Twenty eight 
(32.9%) of patients were presented with septic shock in 
ECB group compared with 14.3% in VREB (P=O.O9). 
Acute mortality rate associated with ECB and VREB 
were 9.4% and 71.4% (PcO.001). Most E. coli isolates 
were susceptible to ceftazidime (lOO%), cefepime 
(100%) amikacin (94.1%) and at least one antibiotics 
used empirically were susceptible. But, 94.1% of E. coli 
were resistant to ciprofloxacin, the prophylactic 
antibiotics for gut decontamination. 
Conclusions: In spite of neutropenia and septic shock, 
most patients of ECB were recovered. Persistence of 
neutropenia, co-infection with fungus were associated 
with high mortality rate. 
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Background: This study was to investigate the etiologic 
organisms, risk factors, and other infectious features of 
septic shock in the hematology and oncology patients 
with neutropenic fever. 
Methods: We reviewed medical record of 671 patients 
receiving chemotherapy or hematopoietic stem cell trans- 
plantation (HSCT) at Catholic HSCT Center from Jan 
1998 to Dee 1999, and found out 457 patients developing 
neutropenic fever. Out of them, 39 patients developing 
septic shock as initial manifestation were enrolled into 
case group and age/sex matched 267 patients without 
hypotension were enrolled into control group. 
Results: There were 177 men and 129 women, with a 
median age of 31 years. Overall incidence of septic shock 
was 8.5%. Most common underlying disease of the two 
groups was acute leukemia. Infections were classified as 
31 MDI, 4 CDI, and 4 UF in the case group, whereas the 
control group had 105, 112,49, respectively (P<O.OOl). 
Thirty-seven microorganisms were isolated as causative 
agents in 31 MD1 of the case group. They were 5 gram- 
positive bacteria (13.5%) and 29 gram-negatives 
(78.3%). Whereas 137 microorganisms isolated in the 
MD1 of the control group were 63 gram-positive 
bacteria (45.9%) and 64 gram-negatives (46.7%). 
Relative risk for the gram-negative bacterial infection in 
the case group was 7.20 (P<O.OOl). Escherichia coli was 
the most common organism in the two groups (51.3% vs 
27.7%, P<O.OOl). Most common infection sites were 
respiratory tract in the case group and gastrointestinal 
tract in the control group. And the respiratory tract 
infection was significantly more frequent in the case 
group (P=O.O38). Mean leukocyte count at the onset of 
fever was 207/mm3 and 355/mm3 (P=O.O27) and mean 
duration of total febrile day was 12.3 days and 7.8 days, 
respectively (P=O.OOl). On multivariate analysis, only 
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leukocyte count at the onset of fever was the significant 
risk factor of the septic shock in the patient with 
neutropenic fever. 
Conclusion: As the most common pathogen of the septic 
shock was gram-negative bacteria, especially E. coli, 
more prudent use of glycopeptide might be needed in 
hypotensive patient if there was no evidence of gram- 
positive infection. 
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Purpose: To study the antibacterial resistance pattern 
induced in P aeruginosa following exposure to cipro- 
floxacin. 
Methods: %enty-six clinical isolates of ciprofloxacin- 
susceptible P aeruginosa were exposed to increasing 
concentrations of ciprofloxacin (0.125-4 &ml) over 
a ten day period. Minimum inhibitory concentration 
(MIC) values were determined for ciprofloxacin, 
cefepime, tobramycin, and garenoxacin before and after 
ciprofloxacin exposure. 
Results: 24 out of 26 isolates developed ciprofloxacin 
resistance (final MIC values, 8-64 ug/ml). The MIC 
values prior to ciprofloxacin-exposure were (0.125-4 
for garenoxacin, 0.5-8 kg/ml for 24 out of 26 isolates 
for cefepime, and (0.125-l &ml for tobramycin. Post- 
ciprofloxacin exposure, all isolates demonstrated 
elevated garenoxacin MIC values (8->128 pg/ml). Of 
the 24 cefepime-susceptible isolates, 12 exhibited a >2- 
fold increase in the cefepime MIC values following 
exposure to ciprofloxacin (four became intermediately- 
susceptible to cefepime, and one became cefepime- 
resistant). No changes in tobramycin MIC values were 
recorded. 
Conclusion: The use of ciprofloxacin may induce resist- 
ance to non-quinolone classes of antimicrobial agents in 
P aeruginosa. 
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Mucosal barrier injury (MBI) of the mouth and gut is a 
severe and dose-limiting complication of the ablative 
regimens used to prepare for hematopoietic stem 
cell transplant (HSCT). Gut MB1 results in increased 
permeability of large molecules and decreased absorption 
of smaller molecules. Here we describe the onset of 
gram-positive bacteremia in relation to changes in gut 
permeability and absorption as measured by a multi- 
sugar test. 
Study population: 9 subjects (IDA group) received 
cyclophosphamide 60 mg/kg i.v on days 6 and 5 and total 
body irradiation with 4.5 Gy on days 2 and 1. 
Antithymocyte-globulines (2 mg/kg i.v. on days 8 till 5) 
was given to 4 of them as they were to receive a 
voluntary unrelated transplant. Another 9 subjects were 
given idarubicin (+IDA) 42 mg/M2 by continuous 
infusion for 48 hours on day 12 before cyclophosphamide 
and TBI in preparation for a human leukocyte antigen 
(HLA) matched, mixed lymphocyte culture (MLC) 
negative T-cell depleted sibling HSCI’. All were managed 
throughout the study period with a triple-lumen central 
venous catheter (CVC) that was inserted on day of 
admission. 
Methods: Multi-sugar probes: Before starting chemo- 
therapy (baseline) and on days 7 (only IDA+), 0, +7, 
+14, +21 post HSCT subjects emptied their bladders, 
after an overnight fast and then drank an isotonic 
solution consisting of 5 g lactulose, 1 g L-rhamnose, 0.2 
g 3-0-methylglucose, 0.5 g D-xylose in 100 mL. Urine 
was then collected over 5 h, the total output was 
recorded and an aliquot was stored at 80°C. The sugars 
were detected using high-performance liquid chromato- 
graphy and the fluorescence label 9-fluorenylmethyl 
chloroformate hydrazine. Lactulose/rhamnose (L/R) 
ratios were used as an index of gut integrity. 
Bacteremia: Blood was drawn through each lumen of 
the CVC for culture twice-weekly and also peripherally 
at the onset of fever. Bacteremia was considered present 
when any organism was recovered from a single blood 
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